培菲康和雷贝拉唑钠及阿莫西林克拉维酸钾治疗幽门螺杆菌阳性患者的疗效观察

Clinical effect of Peifeikang combined with Rabeprazole and Amoxicillin,Clavulanate for helicobacter pylory eradication

目的探讨序贯疗法治疗幽门螺杆菌(Hp)阳性患者的疗效及安全性。方法 108例Hp阳性胃病患者随机分为:对照组(n=54)进行14d传统三联疗法,治疗组(n=54)给予10d序贯疗法(雷贝拉唑钠+阿莫西林克拉维酸钾片前5d,雷贝拉唑钠+培菲康后5d),疗程结束7～10d后检查Hp清除率和消化性溃疡愈合情况,进行观察比较。结果 Hp清除率治疗组为85.19%,对照组为68.52%,差异显著(P<0.05)。溃疡愈合率对照组为28.57%,治疗组为42.86%,差异有统计学意义(P<0.05)。对照组不良反应率为16.67%(9/54),治疗组不良反应率为7.41%(4/54),差异显著(P<0.05)。结论培菲康和雷贝拉唑钠、阿莫西林克拉维酸钾的10d序贯疗法治疗Hp阳性患者疗效肯定且安全。

Objective To study the safety and efficacy of sequential therapy of helicobacter pylori（Hp） positive patient.Methods Totally 108 cases of Hp positive stomach disorder were randomly divided into： control group（n=54） 14 d traditional triple therapy,the treatment group（n=54） give 10 d sequential therapy（ray Bella azole sodium and amoxicillin clavulanic acid potassium tablet before 5 d,ray Bella azole sodium and culture fe kang after 5 d）,treatment over 7-10 d after check Hp clearance and peptic ulcer healing,were observed and compared.Results Hp clearance rate of treatment group is 85.19% and 68.52% in control group,the difference was significant（P0.05）.Ulcer healing rate to 28.57% in the placebo group,the treatment group was 42.86%,the difference was statistically significant（P0.05）.Control group adverse reaction rate was 16.67%（9/54）,treatment group adverse reaction rate was 7.41%（4/54）,significant difference（P0.05）.Conclusions Culture fe kang rabeprazole sodium sodium,amoxicillin clavulanic acid potassium 10 d sequential therapy Hp positive patients with curative effect affirmation and safety.